Thirty-five Day Fluoxetine Treatment Limits Sensory-Motor DeÞcit and Biochemical Disorders in a Rat Model of Decompression Sickness

Authors
C Cosnard, S De Maistre, J H Abraini, L Chazalviel, J-E Blatteau, J-J Risso, N Vallee


Lab
Equipe Résidante de Recherche Subaquatique Opérationnelle, Département Environnement OpŽrationnel, Unité Environnements Extrêmes, Institut de Recherche Biomédicale des Armées, Hopital d'instruction des Armées Sainte-Anne, Toulon, France

Journal
Frontiers in Physiology

Abstract
According to the OECD statistical base for 2014, anti-depressants will, on average, be distributed at a rate of 62 daily doses per 1,000 inhabitants for the 25 countries surveyed (Health at a glance: Europe 2014; OECD Health Statistics; World Health Organization and OECD Health Statistics, 2014). Divers must be concerned. On another hand, divers are potentially exposed to decompression sickness including coagulation inßammation and ischemia, which can result in neurological lesions or even death. The purpose of this study is to assess whether chronic treatment with anti-depressants may represent a contraindication to the practice of an at-risk activity, such as, scuba diving, or even presents a beneÞt by attenuating the severity of the symptoms. We study for the Þrst time the effect of a 35-day ßuoxetine treatment (20 mg/kg) on the occurrence of decompression sickness in laboratory rats (n = 79). Following exposure to the hazardous protocol, there is a signiÞcant correlation between the type of treatment and the clinical status of the rats in favor of a better clinical prognosis for the rats treated with ßuoxetine with a signiÞcantly higher number of No DCS status and a lower number of Severe DCS status in the Flux, compared to Controls. The treatment modiÞes the rat performances both signiÞcantly and favorably during the physical and behavioral tests, just like their biological and biochemical constants. After decompression, rats under treatment display lower sensory-motor deÞcit and lowers biochemical disorders. From a biological point of view, we conclude ßuoxetine should not be seen as a contraindication for diving on the basis of anticipated increased physiological risk.

BIOSEB Instruments Used:
Dynamic Weight Bearing 2.0 (BIO-DWB-DUAL)

DEMANDE DE PUBLICATION

Merci de votre intérêt pour notre gamme de produits et de votre demande pour cette publication qui vous sera envoyée si l'équipe de recherche et la revue le permettent. Notre équipe commerciale vous contactera dans les plus brefs délais.